- Clover research published and highlighted on cover of The Journal of Immunology
- Showed that a soluble IL-20R2 construct binds & blocks all three IL-20 family cytokines (IL-19, IL-20, IL-24) and demonstrated therapeutic efficacy in rheumatoid arthritis animal model
- Filed intellectual property for therapeutic applications of the related inventions & discoveries
CHENGDU, CHINA, 15 October 2016 – Clover Biopharmaceuticals, a biotechnology company focused on developing biologic therapies for oncology and autoimmune diseases, today announced the publication of its research on IL-20R2 and IL-20 family cytokines (IL-19, IL-20 and IL-24) in The Journal of Immunology, a respected peer-reviewed scientific journal. Additionally, Clover’s research paper has been selected by the journal for the front cover of this publication. These accomplishments demonstrate Clover’s in-house discovery, research & development capabilities and its commitment to scientific excellence.
Publication details are as follows:
Title: “A broad blockade of signaling from the IL-20 family of cytokines potently attenuates collagen induced arthritis”
Authors: Xinyu Liu, Hong Zhou, Rongchuan Zhao, Ruoxuan Yu, Tianzhen Long, Yang Xua, Haipeng Liu, Guangping Luo, Xueqin Huang, Joshua G. Liang and Peng Liang
Publication Issue: The Journal of Immunology, Volume 197, Number 8, October 15, 2016.
“We are delighted and honored to have our research on IL-20R2 and IL-20 family of cytokines selected by The Journal of Immunology to be published and highlighted on the cover of its most recent issue,” said Dr. Peng Liang, co-founder, Chairman and President of Clover, who also discovered IL-24 and its receptors. “We have a robust pipeline of transformative biologic therapies, and we are constantly trying to better understand the biological pathways in debilitating, but poorly-understood diseases such as rheumatoid arthritis and related autoimmune conditions.”
He continued: “We are the first to show that a soluble IL-20R2 construct simultaneously blocks all three IL-20 family of cytokines (IL-19, IL-20 and IL-24) and demonstrates therapeutic efficacy in an important autoimmune disease animal model. Whether by utilizing our IL-20R2-Fc fusion protein or a monoclonal antibody targeting IL-20R2, we believe IL-20R2 could be an important new therapeutic target moving forward.”
Concurrent with the publication of this paper, Clover has filed intellectual property, covering the inventions & discoveries relating to the use of antagonists of the IL-20 family of cytokines via IL-20R2.
About Clover Biopharmaceuticals
Clover Biopharmaceuticals is a Chinese biotechnology company focused on discovering, developing and commercializing transformative biologic therapies, with a focus on oncology and autoimmune diseases. Clover is utilizing its proprietary Trimer-Tag© technology to develop novel biologics targeting trimerization-dependent pathways, in addition to developing select biosimilars. Founded by a team of world-renowned scientists returning to China and with biologics manufacturing expertise, Clover aims to bring its therapies to China and the world. For more information, please visit our website: www.cloverbiopharma.com.